TNG Share Price

Open 2.63 Change Price %
High 2.64 1 Day -0.03 -1.15
Low 2.58 1 Week -0.05 -1.89
Close 2.59 1 Month -0.08 -3.00
Volume 69882 1 Year -0.10 -3.72
52 Week High 3.48
52 Week Low 2.27
TNG Important Levels
Resistance 2 2.65
Resistance 1 2.62
Pivot 2.60
Support 1 2.56
Support 2 2.53
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
BRS 12.00 0.00%
BRS 12.00 0.00%
More..
EPA France Top Gainers Stocks
MLPHW 0.85 30.77%
VRNL 0.75 29.31%
MLNOV 7.64 29.05%
ALALO 0.05 25.00%
APAM 33.78 15.72%
APAM 33.78 15.72%
MLLOI 3.80 15.15%
DEXB 17.47 13.89%
DEXB 17.47 13.89%
SIPH 63.00 13.31%
More..
EPA France Top Losers Stocks
MLGEO 0.05 -16.67%
ITL 15.00 -11.30%
ITL 15.00 -11.30%
MLEVE 0.08 -11.11%
BAIN 32.59 -6.75%
LAF 20.61 -6.74%
ALDIE 1.30 -6.47%
GUI 1.47 -5.16%
GUI 1.47 -5.16%
GUI 1.47 -5.16%
More..

Transgene (EPA: TNG)

TNG Technical Analysis 4
As on 24th Mar 2017 TNG Share Price closed @ 2.59 and we RECOMMEND Sell for LONG-TERM with Stoploss of 2.73 & Strong Sell for SHORT-TERM with Stoploss of 2.68 we also expect STOCK to react on Following IMPORTANT LEVELS.
TNG Target for March
1st Target up-side 2.75
2nd Target up-side 2.81
3rd Target up-side 2.87
1st Target down-side 2.59
2nd Target down-side 2.53
3rd Target down-side 2.47
TNG Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.transgene.fr
TNG Address
TNG
400 Boulevard Gonthier d
Parc d
Illkirch-Graffenstaden, 67405
France
Phone: 33 3 88 27 91 00
Fax: 33 3 88 27 91 11
TNG Latest News
BRIEF-Transgene SA says first results from Phase 2 trial could be expected ...   Reuters   - 13th Mar 17
BRIEF-Transgene: First patient of ISI-JX trial treated   Reuters   - 13th Feb 17
Transgene Announces Financial Calendar for 2017   Business Wire (press release)   - 05th Jan 17
Transgene Presents Pre-Clinical Data at AACR on a New Generation Oncolytic ...   Business Wire (press release)   - 19th Apr 16
Transgene and ABL Announce the Acquisition by ABL Europe of Transgene's ...   Business Wire (press release)   - 03rd Feb 16
Transgene Enters New Phase in Its Strategic Development   Business Wire (press release)   - 07th Jan 16
Transgene and SillaJen Announce Revised Agreement for Pexa-Vec Oncolytic Viral ...   Business Wire (press release)   - 12th Nov 15
Transgene Announces Dosing of First Patient with TG1050 for Treatment of ...   Business Wire (press release)   - 04th Nov 15
Transgene Announces Final Overall Survival Data from Phase 2b TIME Trial with ...   Business Wire (press release)   - 08th Sep 15
Transgene Plans Restructuring to Focus on Research and Development   Business Wire (press release)   - 29th Jun 15
Interactive Technical Analysis Chart Transgene ( TNG EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Transgene
TNG Business Profile
Transgene S.A., a biopharmaceutical company, engages in the research, design, development, and manufacture of therapeutic vaccines and immunotherapeutic products to treat cancers and chronic infectious diseases. Its principal products under Phase II clinical trials include TG4010 for the treatment of metastatic non-small cell lung cancer in combination with chemotherapy; Pexa-Vec primarily for the treatment for liver cancer; TG4001, a therapeutic vaccine for oropharyngeal cancer caused by an infection by the human papilloma virus (HPV); and TG4040 for the treatment of chronic hepatitis C. The company has agreements with Novartis for the development of TG4010 to treat various cancers; Jennerex Biotherapeutics, Inc. for the development and marketing of Pexa-Vec, an oncolytic product; and European Organization for Research and Treatment of Cancer for the development of TG4001 to treat HPV induced head and neck cancers. The company was founded in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene S.A. is a subsidiary of TSGH SAS.